The Earnings Debate

Medtronic plc reported first quarter fiscal year 2027 financial results, including "revenue of $9.8 billion" for the quarter, up "13.7% on both the reported and organic basis." This performance "benefited from the extra selling week, which we estimate contributed approximately $570 million or 670 basis points to total organic enterprise revenue growth." The company delivered first quarter "adjusted EPS of $1.45," which was "$0.06 above the midpoint of our guidance range." First quarter "adjusted gross margin was 65.2%," which was "up 10 basis points year-over-year," and "adjusted operating profit was $2.3 billion," an increase of "15% year-over-year." This resulted in a first quarter "adjusted operating margin of 23.7%, up 10 basis points from the prior year." Adjusted SG&A was "32.4% of revenue" and adjusted R&D was "7.9% of revenue in Q1." The company noted that cash conversion was at "70%" for the first quarter.In business updates, Medtronic highlighted that its Cardiac Ablation Solutions business delivered "88% worldwide growth" in the first quarter, driven by the "Sphere-9 momentum" which "continued with a 9-point increase in U.S. share during the quarter," and the business "surpassed the $2 billion mark in trailing 12-month revenue." In Neuroscience, "Cranial & Spinal Technologies delivered 13% growth worldwide" and the recently launched "Stealth AXiS platform also meaningfully outperformed this quarter." In Pelvic Health, procedures for "Altaviva" "doubled sequentially." In Surgical, the "Hugo" robotic platform is expected to "surpass 50,000 completed procedures" by the end of the fiscal year.

The company announced a "strategic investment and distribution agreement for Cornerstone's Sentire Surgical System in select markets outside the U.S." and a "strategic investment" in "Pi-Cardia," which is "the first FDA-cleared leaflet modification technology for TAVR procedures." Medtronic also completed its acquisition of "Scientia" and is on track with the "separation of MiniMed" which they "intend to close prior to fiscal year-end."For forward guidance, Medtronic is raising its "fiscal year '27 organic revenue growth guidance to 7.25% to 7.75%," representing a "50 basis points increase from our prior guidance." For the second quarter of fiscal year 2027, the company expects "roughly 6% organic revenue growth" and adjusted "EPS in the range of $1.32 to $1.34." Foreign exchange is projected as a "roughly $50 million to $150 million headwind for the full year with approximate $25 million to $75 million headwind in 2Q." For the full fiscal year 2027, the company expects "operating profit to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year." Finally, Medtronic is raising its full-year fiscal 2027 adjusted EPS guidance range to "$5.94 to $6."Would you like me to draft some social media posts or create a slide deck outline based on these first quarter fiscal year 2027 results?

What is The Earnings Debate?

We turn quarterly earnings calls into a fast-paced financial comedic debate. Our AI hosts (one skeptic and one optimist) agree on almost nothing. We cut through jargon, pressure-test claims, and spotlight the questions that matter. Rigorous analysis. Actual laughs.
On the beat so you don't miss a beat.